In any serious Turkish M&A transaction, competition law is not a side issue. It is often the legal discipline that determines whether the deal can close, when it can close, how the documents should be drafted, and what conduct is permissible between signing and completion. Under Turkish law, certain mergers and acquisitions require notification to and authorization from the Competition Board in order to become legally valid. That alone makes competition analysis one of the first workstreams that buyers, sellers, and investors should address in a Turkish transaction. The Turkish Competition Authority’s 2025 Mergers and Acquisitions Overview Report underlines how active this area is: the Authority examined 416 merger, acquisition, and privatization transactions in 2025, the highest annual figure in the last thirteen years, and reported an average final-decision period of 10 days after the final date of notification for notified transactions.
The legal backbone of Turkish merger control is Act No. 4054 on the Protection of Competition and Communiqué No. 2010/4 on the Mergers and Acquisitions Calling for the Authorization of the Competition Board. The Competition Authority’s guidance explains that a transaction falls within merger control when it creates a lasting change in control, whether through shares, assets, contracts, or other instruments. This is why competition risk in Turkish M&A cannot be assessed only by looking at the nominal percentage of shares being transferred. A minority investment can still trigger competition-law issues if the buyer obtains decisive influence over strategic decisions.
A second reason competition law is so important in Turkey is that the law does not merely regulate substantive competitive harm. It also regulates procedure, timing, and conduct. A transaction that should have been notified cannot become legally valid before authorization, and a transaction that is implemented early may expose the parties to fines and, in serious cases, corrective measures. That means Turkish competition law risk in M&A is both a clearance risk and an execution risk.
Why competition law is the central execution risk
In many jurisdictions, parties assume that competition-law review matters only in obviously large or heavily concentrated deals. In Turkey, that assumption can be costly. The Competition Authority’s rules cover mergers, acquisitions, and full-function joint ventures that cause a lasting change in control. The same framework also makes clear that intra-group transactions and transfers that do not change control generally fall outside the regime, while acquisitions of control over all or part of an undertaking can fall inside it. In practice, the first competition-law risk is therefore misclassification: parties think they are signing a simple investment or restructuring, when the Authority may view the deal as a concentration.
This risk is especially visible in governance-heavy minority deals. The Competition Authority’s control guideline emphasizes that what matters is decisive influence, whether legal or factual, sole or joint. Veto rights over budget, business plan, senior management, or strategic commercial policy can matter more than raw shareholding percentage. In other words, a buyer can create Turkish merger-control exposure without acquiring majority ownership. That is one of the most common hidden risks in private equity, venture capital, family office, and joint venture transactions involving Turkish targets.
The risk also appears in staged or linked transactions. The Authority’s guidance explains that where serial steps are inter-conditional and ultimately produce a single change in control, they may be treated as one concentration. Türkiye’s official note on serial acquisitions and industry roll-ups likewise confirms that the current turnover thresholds apply to qualifying concentrations and highlights the Authority’s attention to serial acquisition patterns. For deal lawyers, that means a transaction cannot always be analyzed one step at a time; sometimes the Authority will look at the commercial whole.
The threshold risk: when filing becomes mandatory
The most obvious competition-law risk is the risk of failing to notify a transaction that crosses the Turkish filing thresholds. According to the Competition Authority’s 2025 report, authorization is required where either:
the total Turkish turnovers of the transaction parties exceed TRY 750 million and at least two parties each have Turkish turnover exceeding TRY 250 million; or, in acquisitions, the target asset, activity, or business has Turkish turnover exceeding TRY 250 million and another transaction party has global turnover exceeding TRY 3 billion. The Authority also states that transactions implemented abroad must still be notified in Turkey if those thresholds are met.
This is a major risk for international deals. Foreign buyers sometimes assume that a foreign-to-foreign transaction will be reviewed only in the parties’ home jurisdictions or in Brussels. Turkish law does not work that way. If the Turkish nexus satisfies the filing thresholds, the transaction may need Turkish clearance even if the signing takes place abroad and the target sits outside Turkey. For multinational groups, that creates a classic timing risk: a deal team may be ready to close globally while still needing Turkish authorization.
There is also a more recent procedural risk. On 11 February 2026, the Competition Authority announced that it had updated the M&A legislation, including amendments to Communiqué No. 2010/4, the Notification Form, and some explanatory guidelines. For transaction practice, that means parties should not recycle an old filing template or rely on an outdated internal checklist. Even where the substantive transaction looks familiar, the filing mechanics and definitions should be checked against the current materials.
Technology undertaking risk
One of the most important modern competition-law risks in Turkish M&A is the technology undertaking rule. Communiqué No. 2010/4 defines technology undertakings broadly to include businesses active in digital platforms, software and gaming software, financial technologies, biotechnology, pharmacology, agricultural chemicals, and healthcare technologies, or the assets of such businesses. The Communiqué further provides a special rule under which the standard local threshold does not apply in the ordinary way for certain acquisitions involving technology undertakings operating in the Turkish geographic market, carrying out R&D in Turkey, or providing services to Turkish users.
This creates a specific Turkish M&A risk for startup acquisitions and digital-economy deals. A target may have modest Turkish revenue today but still fall within the Authority’s focus because of its technology profile, Turkish users, or Turkish R&D footprint. Buyers in software, gaming, fintech, data-driven services, health tech, and platform markets therefore need a much earlier competition-law screen than traditional turnover analysis might suggest.
The practical lesson is that the usual internal question, “How much Turkish revenue does the target make?” is no longer enough by itself. In technology transactions, the better question is, “Does the target qualify as a technology undertaking with a Turkish nexus?” If the answer may be yes, the risk of a missed filing rises sharply.
Gun-jumping and premature integration risk
Another major competition-law risk in Turkish M&A is gun-jumping. The Turkish system is suspensory: a notifiable transaction cannot become legally valid before the Board authorizes it. The Communiqué states this directly, and the official OECD note submitted by Türkiye explains that implementing a notifiable concentration without approval can lead to fines under Article 16 of the Competition Act. That note also explains that the fine for implementing without authorization is based on Article 16 and describes the administrative fine as one in a thousand of annual gross revenues, imposed on both parties in mergers and on the acquirer in acquisitions.
Gun-jumping is not limited to formal closing. The real risk begins earlier, during the period between signing and clearance. If the buyer begins to direct the target’s commercial strategy, influence pricing, allocate customers, control supplier negotiations, or integrate sensitive operations before approval, the parties may create implementation risk even if the formal share transfer has not yet been completed. Turkish law’s focus on change in control means that substance matters more than labels. A clause in the SPA calling something an “interim covenant” will not cure conduct that effectively transfers decisive influence too early.
This is why clean-team protocols and signing-to-closing governance rules matter in Turkish deals. The safest approach is to preserve the target’s independent commercial decision-making until authorization arrives, while allowing only the limited protective measures genuinely needed to preserve the value of the business. Where the deal team ignores this distinction, the competition-law problem may arise from conduct, not only from the transaction itself.
Substantive review risk: horizontal, vertical, and conglomerate concerns
Even when the filing is made on time, the next risk is substantive. Turkish law does not stop at formal notification. The Board assesses whether the transaction will lead to a significant lessening of effective competition. The Authority’s March 2026 Horizontal Mergers and Acquisitions Guidelines explain that the Board considers whether the transaction will lead to significant lessening of effective competition and treats the creation or strengthening of dominance as an important indicator of competitive harm.
For horizontal transactions, the obvious risks are overlap, concentration, and the removal of an important competitive constraint. But the Authority’s approach is not mechanical. The horizontal guideline indicates that the Board examines whether competition will be significantly lessened, not merely whether the parties’ combined share exceeds a symbolic number. Market structure, rivalry intensity, customer choice, entry conditions, and the identity of close competitors can all matter. This means that even deals below headline-dominance narratives can still present Turkish competition-law risk if they materially weaken rivalry.
Non-horizontal deals also deserve caution. The Authority’s Non-Horizontal Mergers and Acquisitions Guidelines explain that non-horizontal transactions include vertical and conglomerate mergers. Vertical deals can raise upstream and downstream foreclosure concerns, while conglomerate combinations may matter where complementary products, product ranges, or linked commercial ecosystems allow the merged group to strengthen market power in a way rivals cannot easily match. The risk in Turkish practice is assuming that “no horizontal overlap” means “no competition issue.” It does not.
In digital and data-heavy transactions, this point becomes even more important. A platform acquisition, a software-plus-distribution deal, or a complementary-data transaction may trigger scrutiny not because the parties sell the exact same product today, but because the combined business could foreclose rivals, degrade interoperability, leverage user data, or lock customers into a broader ecosystem. Turkish merger analysis has moved well beyond old-fashioned factory-to-factory overlap cases.
Information exchange and pre-closing coordination risk
Competition-law risk in Turkish M&A also arises during due diligence and integration planning. Buyers want commercially sensitive information before they sign or close. Sellers want to show value. But competition law draws a line between legitimate diligence and problematic information exchange. If actual or potential competitors share current or future pricing, customer strategy, commercially sensitive volumes, or rival-by-rival plans without adequate safeguards, the diligence process itself can become risky. Turkish competition enforcement materials repeatedly show the Authority’s concern with the exchange of competitively sensitive information in concentrated markets.
That does not mean due diligence is forbidden. It means diligence must be structured. Aggregated data, delayed information, outside advisers, ring-fenced teams, and clean-team protocols are often necessary where the parties compete. The more competitively close the parties are, the stronger the internal protections should be. In Turkish M&A, bad information hygiene can transform a routine diligence process into an Article 4 problem, even before the merger-control analysis is complete.
Ancillary restraints risk
Another underappreciated Turkish M&A competition risk concerns ancillary restraints. Non-compete clauses, non-solicitation clauses, transitional supply obligations, exclusivity provisions, IP licenses, and similar covenants are common in acquisition documents. The Competition Authority’s guideline on undertakings concerned, turnover, and ancillary restraints explains that restrictions directly related to and necessary for the implementation of a concentration may be treated as ancillary restraints. But the same logic carries a warning: parties themselves remain responsible for staying within that boundary.
The drafting risk is obvious. A narrowly tailored non-compete protecting transferred goodwill may be defensible; an overbroad customer restriction or an excessive duration may not be. The same is true for no-poach clauses or exclusivity commitments. If the restraint goes beyond what is necessary to implement the deal, it may fall outside merger clearance and need separate analysis under competition rules. In short, Turkish merger approval does not automatically sanitize every restrictive covenant buried in the SPA.
Remedies and conditional clearance risk
Some Turkish deals do not present a simple yes-or-no outcome. Communiqué No. 2010/4 allows the parties to offer commitments in order to eliminate competition problems arising under Article 7, and the Board may attach conditions and obligations to ensure those commitments are fulfilled. The Authority’s reports also refer to its remedies guidance in merger and acquisition transactions. For transaction planning, that means a competition issue does not always kill a deal, but it can reshape it.
The practical risk here is deal certainty. If remedies become necessary, the parties may need to divest assets, amend governance, alter commercial arrangements, or accept ongoing obligations. That can affect price, integration logic, timetable, and financing. A buyer that underestimates remedy risk may discover too late that the transaction it modeled is not the transaction the Authority is willing to clear.
Practical conclusion
Competition law risks in Turkish mergers and acquisitions can be grouped into four core questions. Is the transaction a concentration? Does it cross the filing thresholds? Can the parties avoid premature implementation before clearance? Will the transaction materially weaken competition horizontally, vertically, or through ecosystem effects? If those four questions are answered late, the transaction becomes harder, slower, and more expensive.
The best Turkish M&A practice is therefore front-loaded. Control analysis should be done before the term sheet hardens. Threshold analysis should be done before signing. Information-sharing limits should be designed before diligence begins. Ancillary restraints should be drafted with proportionality in mind. And because the Authority announced an update to the M&A legislation package in February 2026, counsel should verify the latest filing rules and forms at the outset rather than assuming that last year’s documents are still current.
For buyers, sellers, founders, and investors, the commercial takeaway is simple: in Turkey, competition law is not merely a filing issue. It is a transaction design issue. A deal that looks commercially attractive can still fail because control was misread, a technology trigger was ignored, a filing was missed, interim covenants went too far, or the parties coordinated too early. The safest and most effective Turkish M&A transactions are the ones where competition law is built into the structure from day one, not patched in after signing.
Yanıt yok